Zhejiang Hisun Pharmaceutical And Alpharma To Set Up Joint Venture
This article was originally published in PharmAsia News
Zhejiang Hisun Pharmaceutical has signed an MOU with Alpharma API Hong Kong to set up a joint venture that produces and sells vancomycin. With a business term of 30 years, a total of $50 million will be allocated for the investment. Hisun will put up 49 percent of the $24.3 million paid-up capital. An informed source believes Hisun's real motivation in the venture is not to produce the low-profit vancomycin active pharmaceutical ingredients, but rather, to take advantage of Alpharma's international brandname and sales channels to market its own pharmaceutical preparations globally. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.